Why the study?
Does the combination of argatroban and nafamostat mesilate provide safe and effective anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia?
Does the combination of argatroban and nafamostat mesilate provide safe and effective anticoagulation during cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia?
The combination of argatroban and nafamostat mesilate can provide effective anticoagulation for cardiopulmonary bypass in patients with HIT, though careful monitoring is required due to prolonged anticoagulant effects and increased transfusion requirements.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: